Mostrar el registro sencillo del ítem

dc.contributor.author Monczor, Federico
dc.contributor.author Copsel, Sabrina Natalia
dc.contributor.author Fernandez, Natalia Cristina
dc.contributor.author Davio, Carlos Alberto
dc.contributor.author Shayo, Carina Claudia
dc.date.available 2017-09-07T19:29:34Z
dc.date.issued 2016-06-18
dc.identifier.citation Monczor, Federico; Copsel, Sabrina Natalia; Fernandez, Natalia Cristina; Davio, Carlos Alberto; Shayo, Carina Claudia; Histamine H2 receptor in blood cells: a suitable target for the treatment of acute myeloid leukemia; Springer; Handbook of Experimental Pharmacology; 241; 18-6-2016; 141-160
dc.identifier.isbn 978-3-319-58194-1
dc.identifier.issn 0171-2004
dc.identifier.uri http://hdl.handle.net/11336/23797
dc.description.abstract Acute myeloid leukemia (AML) consists in a cancer of early hematopoietic cells arising in the bone marrow, most often of those cells that would turn into white blood cells (except lymphocytes). Chemotherapy is the treatment of choice for AML but one of the major complications is that current drugs are highly toxic and poorly tolerated. In general, treatment for AML consists of induction chemotherapy and post-remission therapy. If no further post-remission is given, almost all patients will eventually relapse. Histamine, acting at histamine type-2 (H2) receptors on phagocytes and AML blast cells, helps prevent the production and release of oxygen-free radicals, thereby protecting NK and cytotoxic T cells. This protection allows immune-stimulating agents, such as interleukin-2 (IL-2), to activate cytotoxic cells more effectively, enhancing the killing of tumor cells. Based on this mechanism, post-remission therapy with histamine and IL-2 was found to significantly prevent relapse of AML. Alternatively, another potentially less toxic approach to treat AML employs drugs to induce differentiation of malignant cells. It is based on the assumption that many neoplastic cell types exhibit reversible defects in differentiation, which upon appropriate treatment results in tumor reprogramming and the induction of terminal differentiation. There are promissory results showing that an elevated and sustained signaling through H2 receptors is able to differentiate leukemia derived cell lines, opening the door for the use of H2 agonists for specific differentiation therapies. In both situations, histamine acting through H2 receptors constitutes an eligible treatment to induce leukemic cell differentiation, improving combined therapies.
dc.format application/pdf
dc.language.iso eng
dc.publisher Springer
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject LEUKEMIA
dc.subject HISTAMINE
dc.subject H2 RECEPTOR
dc.subject CELL DIFFERENTIATION
dc.subject.classification Bioquímica y Biología Molecular
dc.subject.classification Medicina Básica
dc.subject.classification CIENCIAS MÉDICAS Y DE LA SALUD
dc.subject.classification Patología
dc.subject.classification Medicina Básica
dc.subject.classification CIENCIAS MÉDICAS Y DE LA SALUD
dc.title Histamine H2 receptor in blood cells: a suitable target for the treatment of acute myeloid leukemia
dc.type info:eu-repo/semantics/article
dc.type info:ar-repo/semantics/artículo
dc.type info:eu-repo/semantics/publishedVersion
dc.date.updated 2017-08-31T20:29:37Z
dc.identifier.eissn 0171-2004
dc.journal.volume 241
dc.journal.pagination 141-160
dc.journal.pais Estados Unidos
dc.journal.ciudad Nueva York
dc.description.fil Fil: Monczor, Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Farmacológicas. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones Farmacológicas; Argentina
dc.description.fil Fil: Copsel, Sabrina Natalia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.description.fil Fil: Fernandez, Natalia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Farmacológicas. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones Farmacológicas; Argentina
dc.description.fil Fil: Davio, Carlos Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Farmacológicas. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones Farmacológicas; Argentina
dc.description.fil Fil: Shayo, Carina Claudia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.journal.title Handbook of Experimental Pharmacology
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/chapter/10.1007%2F164_2016_8
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/164_2016_8
dc.relation.alternativeid info:eu-repo/semantics/altIdentifier/pmid/27316911


Archivos asociados

Icon
Blocked Acceso no disponible

Aparece en la(s) siguiente(s) colección(ones)

  • Articulos(IBYME) [1027]
    Articulos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)